絞り込み

16603

広告

解雇規制緩和という『ブラック・スワン』に備えよ (日経BP)

担当 さて、令和初のコラムのネタなんですけど……どうしましょうね。ってか、センセーはあんまり令和とか、そういうの気にしないでしょうけど。 鈴木 いや、そういうの...

  1. POLO試験の結果は進行膵癌の診療を変え...
  2. 万年研修医の覚悟がないと時代に取り残され...
  3. 認知症の睡眠問題は「診立て」が肝心 (日...
  4. 再製造医療機器流通のために病院が注意すべ...

ニュース一覧

Use of Cardiac MRI to Assess Antitumor Efficacy of Everolimus in Sporadic Cardiac Rhabdomyoma.

著者 Davis KA , Dodeja AK , Clark A , Hor K , Baker P , Cripe LH , Cripe TP
Pediatrics.2019 May 14 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (8view , 0users)

Full Text Sources

Miscellaneous

Cardiac rhabdomyoma is the most common neonatal cardiac tumor and is typically associated with tuberous sclerosis complex (TSC). Although these tumors may naturally regress, some patients require surgical resection because of cardiac instability. If not fully resected, patients may also require medical therapy to improve their hemodynamics. Everolimus, a mammalian target of rapamycin inhibitor, has shown promise in reducing rhabdomyoma in patients with TSC, but the drug's impact in patients without TSC has not been reported. Monitoring of tumor response has typically been limited to echocardiograms, which is not ideal given inherent difficulties in three-dimensional measurements. We report a case of sporadic cardiac rhabdomyoma in a neonate treated with everolimus resulting in tumor regression as documented by cardiac MRI. While on everolimus, our patient had an increased incidence of a preexisting arrhythmia, which resolved with planned cessation of therapy, suggesting that close monitoring is imperative in patients with arrhythmia.
PMID: 31088894 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード